SPCEO1 - (5/20/2022 10:39:20 AM)
RE:Decisions
I presented some possible times when we could get very, very meaningful info on efficacy in TH-1902 yesterday and it is not that far away. The company cannot make such predictions but what I suggested is still likely roughly accurate. While their comunications strategy to the capital markets is very weak the fact remains the phase 1b has started and if we are going to see efficacy in patients chosen because they have the best chance of seeing efficacy, it is most likely going to be in the next few months and under teh best case scenario, by the end of June.
There is also a financing happening somewhere out there soon. That could be good or bad for shareholders depending on what they come up with. The fact they have not yet done a financing may be indicative of an internal belief at TH that they will have positive results soon on TH-1902 and it would be better to do a financing after that than before.
SABBOBCAT wrote: Paull and Philippe,
Now more than ever it is important to effectively sell the TH story by communicating realistic plans and timelines. The pullback in markets has created LOTS of opportunity in names that have been unjustly beat down. I, and others, are over exposed to TH and have missed out on other opportunities in the past. I am struggling to believe we will get any meaningful information in the near term and am considering reallocating a portion of my holdings away from TH. The dearth of communication does not help in uncertain times. Reasserting the thesis along with clear expectations for when results will come helps build trust and credibility with investors. Absent any communication I will be looking elsewhere for my marginal dollars and may reduce exposure to this value trap.